rhIGF-1/BP3在实验性支气管肺发育不良中保护肺生长并预防肺动脉高压
本研究在产前羊膜腔内注射内毒素或sFlt-1以及产后高氧诱导的三种支气管肺发育不良(BPD)大鼠模型中,评估产后给予rhIGF-1/BP3对肺生长和肺动脉高压的影响。结果显示rhIGF-1/BP3治疗可恢复径向肺泡计数和右心室肥厚至正常水平,并保护肺结构,体外实验显示其促进肺内皮细胞和肺泡2型细胞增殖。提示rhIGF-1/BP3可能为预防早产儿BPD提供新策略。
要点
- 产后rhIGF-1/BP3治疗可恢复BPD大鼠模型的径向肺泡计数和右心室肥厚至正常。
- rhIGF-1/BP3在产前和产后BPD模型中均保护肺结构并预防右心室肥厚。
- 体外实验显示rhIGF-1/BP3促进肺内皮细胞和肺泡2型细胞增殖。
核心结论
- 产后rhIGF-1/BP3治疗在产前和产后BPD模型中保护肺结构并预防右心室肥厚。
- rhIGF-1/BP3治疗可能为预防早产儿BPD提供新策略。
研究设计与样本
- 研究在三种BPD大鼠模型中评估产后rhIGF-1/BP3治疗:产前羊膜腔内注射内毒素、产前羊膜腔内注射sFlt-1、以及产后持续高氧。
- 孕鼠在胚胎第20天羊膜腔内给予内毒素或sFlt-1,胚胎第22天剖宫产分娩,幼鼠接受rhIGF-1/BP3(0.02-20 mg/kg/d腹腔注射)或缓冲液治疗2周。
- 研究终点包括径向肺泡计数(RAC)、血管密度和右心室肥厚(RVH)。
- 体外研究用标准方法检测rhIGF-1/BP3(250 ng/ml)对胎肺内皮细胞增殖和管腔形成以及肺泡2型细胞增殖的直接作用。
主要发现
- 产前内毒素和产前sFlt-1降低幼鼠RAC并减少RVH。
- 在两种产前模型中,产后rhIGF-1/BP3治疗与安慰剂注射相比使RAC和RVH恢复至正常值。
- 产后高氧后,rhIGF-1/BP3治疗也保护肺结构并预防RVH。
- 体外研究显示rhIGF-1/BP3治疗增加肺内皮细胞和肺泡2型细胞增殖。
临床怎么用
- 目前证据来自动物实验,尚不能直接用于临床实践;需进一步临床研究验证rhIGF-1/BP3预防早产儿BPD的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Antenatal factors, such as chorioamnionitis, preeclampsia, and postnatal injury, are associated with an increased risk for bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) after preterm birth. IGF-1 (insulin-like growth factor-1) is markedly decreased in normal preterm infants, but whether IGF-1 treatment can prevent BPD or PH is unknown.Objectives: To evaluate whether postnatal treatment with rhIGF-1 (recombinant human IGF-1)/BP3 (binding peptide 3) improves lung growth and prevents PH in two antenatal models of BPD induced by intraamniotic exposure to endotoxin (ETX) or sFlt-1 (soluble fms-like tyrosine kinase 1), and in a postnatal model due to prolonged hyperoxia.Methods: ETX or sFlt-1 were administered into the amniotic sac of pregnant rats at Embryonic Day 20 to simulate antenatal models of chorioamnionitis and preeclampsia, respectively. Pups were delivered by cesarean section at Embryonic Day 22 and treated with rhIGF-1/BP3 (0.02-20 mg/kg/d intraperitoneal) or buffer for 2 weeks. Study endpoints included radial alveolar counts (RACs), vessel density, and right ventricular hypertrophy (RVH). Direct effects of rhIGF-1/BP3 (250 ng/ml) on fetal lung endothelial cell proliferation and tube formation and alveolar type 2 cell proliferation were studied by standard methods in vitro.Measurements and Main Results: Antenatal ETX and antenatal sFlt-1 reduced RAC and decreased RVH in infant rats. In both models, postnatal rhIGF-1/BP3 treatment restored RAC and RVH to normal values when compared with placebo injections. rhIGF-1/BP3 treatment also preserved lung structure and prevented RVH after postnatal hyperoxia. In vitro studies showed that rhIGF-1/BP3 treatment increased lung endothelial cell and alveolar type 2 cell proliferation.Conclusions: Postnatal rhIGF-1/BP3 treatment preserved lung structure and prevented RVH in antenatal and postnatal BPD models. rhIGF-1/BP3 treatment may provide a novel strategy for the prevention of BPD in preterm infants.
引用
- Seedorf G, Kim C, Wallace B, et al. rhIGF-1/BP3 Preserves Lung Growth and Prevents Pulmonary Hypertension in Experimental Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2020. PMID: 32101461. doi:10.1164/rccm.201910-1975OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。